Chuck is Managing Director at AbbVie Ventures where he has been involved in the creation, financing and building of over a dozen biotech companies in the US and Europe since 2013. He has served on the boards of Prevail Therapeutics (sold to Lilly), Tidal Therapeutics (sold to Sanofi), Disc Medicines (IRON), Accent Therapeutics, Kojin Therapeutics, Ribometrix, EndLyz Therapeutics, Quanta Therapeutics, DG Medicines and FireCyte Therapeutics, among others. Prior to AbbVie, Chuck was Vice President of Biology at AtheroGenics and begin his career in biotech at Human Genome Sciences. He obtained his Ph.D. from The Pennsylvania State University College of Medicine and did a post-doctoral fellowship at the Roche Institute of Molecule Biology. Chuck enjoys working with early-stage life science entrepreneurs and volunteering with several funding advisory boards at Yale, Dartmouth, UMass Chan Medical School and The University of Pittsburgh as well as serving on the Board of Trustees of the Massachusetts Biomedical Initiatives.
Charles “Chuck” Kunsch, Ph.D.
Managing Director, AbbVie Ventures